Showing 15 posts of 123 posts found.


Mylan CEO to appear before US congress over EpiPen scandal

September 15, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, Hilary Clinton, Mylan, epipen

Following the controversy of Mylan’s price increases to its EpiPen (epinephrine) auto-injector, the company’s CEO Heather Bresch is due to …


Antitrust investigation launched into Mylan and the EpiPen scandal

September 7, 2016
Research and Development, Sales and Marketing Mylan, US, antitrust, epipen, investigation, lawmakers, scandal

The New York attorney general has commenced an investigation into Mylan Pharmaceuticals, after an initial review indicated that the company …


EMA accepts regulatory submission for proposed Herceptin biosimilar

August 26, 2016
Medical Communications Biocon, EMA, Herceptin, Mylan, biosimilar, regulatory, submission, trastuzumab

Mylan and Biocon have announced that the European Medicines Agency (EMA) has accepted for review its marketing authorisation application for …


Mylan announces immediate plans to cut price of EpiPen

August 25, 2016
Medical Communications, Research and Development Mylan, clinton, epipen, increase

Subject to intense pressure over the last few days, Mylan has made an attempt to avoid becoming “another Valeant” by …


Teva loses patent protection on lucrative MS treatment

August 25, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Copaxone, Mylan, Teva, multiple sclerosis

Teva’s stock plunged 3% after a US agency ruled that two of its patents related to multiple sclerosis drug Copaxone …


Mylan latest target of US anger on drug pricing with EpiPen price increase

August 24, 2016
Research and Development, Sales and Marketing Mylan, US, congress, controversy, epipen, price gouging, price increase

The US congress is again subjecting the pharmaceutical industry to heavy scrutiny over drug pricing policies with Mylan its latest …

Mylan’s breast cancer biosimilar matches Roche’s Herceptin in Phase III trial

June 6, 2016
Research and Development ASCO, Biocon, Herceptin, Mylan, Roche, biosimilar, breast cancer, trastuzumab

Mylan (NASDAQ: MYL) and Biocon (NSE: BIOCON) have presented data the 2016 American Society of Clinical Oncology (ASCO) annual meeting …


Mylan to buy Renaissance’s dermatology business for up to $1 billion

May 16, 2016
Research and Development, Sales and Marketing Mylan, generics, merger and acquisition

Generics maker Mylan (Nasdaq: MYL) has agreed to buy skincare products from Renaissance Acquisition Holdings for up to $1 billion. …


New CFO at Mylan

May 3, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Mylan, cfo, kenneth parks

Mylan has announced the appointment of Kenneth S. Parks as its new chief financial officer, effective June 6 2016. Parks …


Mylan Q1 revenue up 17%, maintains FY view

May 3, 2016
Manufacturing and Production, Sales and Marketing Financial, Mylan, Q1, results, revenue, sales

Pharma firm Mylan NV (Nasdaq: MYL) on Tuesday reported a 17% rise in first-quarter revenue and said it maintains its …


Mylan launches new dosages of generic of Novartis hypertension drug in US

April 11, 2016
Manufacturing and Production Mylan, Novartis, generic, high blood pressure, hypertension

Mylan (TASE: MYL) has announced the US launch of new dosages of its generic version of Novartis’s hypertension drug, Lopressor …


Mylan launches generic of Valeant’s Ultram in the US

March 29, 2016
Manufacturing and Production, Sales and Marketing FDA, Mylan, Valeant, abbreviate new drug application, generic, pain, tramadol, ultram

Mylan (NASDAQ, TASE: MYL) has announced the launch of its generic version of Valeant’s Ultram tablets in the US. The …

Mylan building

Mylan announces Momenta collaboration to develop six biosimilars

January 8, 2016
Manufacturing and Production, Sales and Marketing Heather Bresch, Momenta, Mylan, biosimilars

Mylan has entered an exclusive global collaboration agreement with Momenta Pharmaceuticals, to develop, manufacture and commercialise six of Momenta’s biosimilar …

Justice department

Mylan receives court summons from US Department of Justice

December 7, 2015
Sales and Marketing Drug pricing, Justice department, Mylan, US Department of Justice, generics, investigation, subpoena

The US Department of Justice has contacted Mylan to make enquiries about the company’s pricing structure for antibiotic, doxycycline. Mylan …

Mylan image

Mylan launches digital adherence programme for heart patients

November 27, 2015
Medical Communications Canada, Mavik, Mylan, pharmacies, trandolapril

Mylan has launched an innovative digital medication adherence and engagement program for patients with high blood pressure. The digital programme, called …

Latest content